This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-the-optic-nerve-be-protected-the-new-neuroprotection-era-in-glaucoma-research Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can the Optic Nerve Be Protected? The New Neuroprotection Era in Glaucoma Research Glaucoma has long been called the “silent thief of sight” – historically treated by focusing on intraocular pressure (the fluid pressure in the eye). But a growing body of research shows that glaucoma is not just a plumbing problem. It is also a neurodegenerative disease that gradually destroys the eye’s nerve cells. Imagine your eye as a camera and the optic nerve as the cable that carries its images to your brain. In glaucoma, this cable gets frayed and rusty over time, not only from high pressure but from an internal “wear-and-tear” process. In this article, we’ll explain why that matters, and how new treatments are trying to protect the neural wiring of the eye. We’ll use simple metaphors – nothing too technical – so you can follow along easily. Retinal Ganglion Cells: The Eye’s Messengers Inside the eye’s retina, special nerve cells called retinal ganglion cells (RGCs) work like telephone wires, carrying visual signals from the eye to the brain. Each eye has about 1.5 million of these cells, whose long fibers bundle together into the optic nerve (). Think of RGCs like millions of tiny light bulbs along a cable: when light hits the retina, RGCs convert that information into electrical signals that zoom up the optic nerve to the brain. RGCs are crucial. Once they die, our vision is lost in those areas – they do not regenerate on their own. As one review bluntly puts it, glaucoma is marked by the “irreversible loss of retinal ganglion cells (RGCs)” (). In other words, if these cells “burn out,” the damage is permanent. A 2021 study of lab-transplanted RGCs emphasizes that because RGCs “transmit visual information from the retina to the brain, their progressive loss results in fading vision and, ultimately, blindness” (). In everyday terms, losing RGCs is like cutting fibers in a cable – the signal can’t get through, and you get a blind spot or fair-sized dark area in your vision. Because RGCs do so much work, they burn a lot of energy. They’re packed with tiny power plants called mitochondria, and they need good blood flow and nutrients. This makes them shinny glass in a storm: delicate and easily damaged. In glaucoma, anything that weakens RGCs – from starvation of blood to chemical “rust” – can cause them to die. Glaucoma: More Than Just High Eye Pressure Traditionally, doctors have measured eye pressure as the key glaucoma risk. High pressure can physically squeeze the optic nerve fibers as they exit the eye (like pressing on a cable at the wall). This pressure can block roads for nutrients, slow down the traffic of essential chemicals, and trigger cell damage (). But scientists now understand that high pressure is only one piece of the puzzle. In many patients, something else is at work hurting those nerve cells, even when pressure is normal. Neurodegeneration and the Brain In fact, glaucoma is increasingly seen as similar to other nerve diseases like Alzheimer’s or Parkinson’s, but focused on the eye and its brain connection. Studies have found that damaging glaucoma can spread beyond the eye all the way into the brain’s visual centers (). For example, a recent review explains that people with glaucoma often show changes in their brain, such as thinning of visual cortex or altered neural connections – much like early Alzheimer's patients (). This hints that glaucoma triggers a kind of “domino effect” of damage along the visual pathways, not unlike what happens with other neurodegenerative diseases. Mechanistically, researchers are finding shared culprits between glaucoma and brain diseases: things like broken mitochondria, chronic inflammation, and clogged nerve transport systems (). In simple terms, if Alzheimer’s is a problem of aging brain cells, glaucoma may be a related problem of aging eye cells (RGCs) and their brain links. Beyond Pressure: Inflammation, Oxidative Stress, and Vascular Factors Because glaucoma is more than just “too much fluid,” other harmful processes are blamed when we see vision worsen despite good pressure control. One key factor is inflammation. The eye – like the brain – has immune-support cells (glia) that can overreact when stressed. Stressed RGCs send out danger signals such as reactive oxygen species (free radicals), nitric oxide, and inflammatory proteins (like TNF-α and interleukins) (). This can trigger chronic inflammation that ironically damages the very neurons it was meant to protect. Here’s an analogy: imagine RGCs as factories. When something goes wrong (like machinery overheating), the factory alarms (inflammatory signals) go off. If the alarm system is too sensitive or stuck on, it can end up hurting the factory itself, not helping it. In glaucoma, exhausted RGC mitochondria may flood the retina with reactive oxygen (oxidative stress) that activates this “alarm,” causing friendly fire against nerves (). One review on glaucoma neuroinflammation describes how broken mitochondria in RGCs can set off the immune system, leading to a sustained damaging response (). In short: when RGC energy centers fail, they trigger a damaging inflammation loop within the eye. Vascular factors also play a role. The tiny blood vessels that feed the optic nerve can be sensitive. Eyedrops that raise heart rate or conditions like diabetes and high blood pressure can affect blood flow to the eye. Low blood pressure (especially at night) or vascular “spasms” are linked to worse glaucoma because they temporarily starve RGCs of oxygen (). For instance, one comprehensive review notes that reduced blood perfusion pressure and faulty blood vessel regulation likely help drive RGC damage (). In our cable analogy, this is like having power fluctuations in the electrical grid; even if the cable and camera are fine, if the power supply is shaky, the system falters. This is why glaucoma specialists often pay attention to cardiovascular health and sometimes even advice moderating certain blood pressure medications at night. Why Pressure Control Isn’t Always Enough All these factors explain why some patients keep losing vision even when their eye pressure is low or normal. For example, “normal-tension glaucoma” is a common scenario where eye pressure never gets high, yet RGC damage and optic nerve cupping progress (). Conversely, in some patients with high pressure, lowering it stops further damage. But in many others, damage creeps on. As one expert noted, despite “apparently good” pressure readings, disease can worsen in a number of patients (). In other words, lowering pressure is necessary but sometimes not sufficient. A meta-analysis of patient studies put it starkly: doctors have observed that RGC loss often “continues despite lowering IOP,” meaning that treatments only focused on pressure “may not be beneficial for some glaucoma patients” (). Think of blood pressure for analogy: lowering blood pressure helps most high-risk people, but if someone is still leaking cholesterol plaques or has other heart risks, they may still have a heart problem despite normal pressure. Similarly, in glaucoma we must also target the nerve itself, not just the fluid pressure. The Search for Neuroprotective Treatments Since RGCs are dying by many causes, scientists have searched for neuroprotective strategies: treatments that can keep these nerve cells alive longer or healthier. In simple terms, neuroprotection means anything aimed at preventing nerve damage or death (). This new era of research looks beyond pressure: it asks, “How can we shield the optic nerve from harm, regardless of the pressure?” Researchers are exploring many avenues, from drugs to diet to bioengineering. Here are some current and emerging strategies being studied: Neuroprotective Eye Medications: Some existing glaucoma drugs might have nerve-saving effects. For example, brimonidine (an eye drop that lowers pressure) was hoped to strengthen RGC survival. Lab studies in animals showed promise, but human trials have so far been disappointing (). An evidence review reports that to date, clinical trials of such “neuroprotectors” have failed to show clear benefits in people (). Another drug, memantine (used in Alzheimer’s), was tested in large glaucoma trials but did not prove effective. At present, manufacturers have not reported any significant vision benefit, so memantine is not part of glaucoma care. In short, while drugs like these are studied, none are yet a proven neuroprotective cure. Growth Factors and Gene Therapy: Scientists have tried giving eyes extra “growth factors” – proteins that help nerves survive and grow. For example, nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) can keep RGCs from dying in animals. Experiments involving viral gene therapy are in early stages: for instance, researchers can inject a harmless virus carrying genes for protective proteins into the eye. One phase-1 trial (GVB-2001) is even testing a gene treatment to relax eye muscles for pressure control (), and similar approaches might deliver neuroprotective genes later on. These techniques are still experimental. The hope is to one day use gene vectors to make the eye produce its own protective agents, but it is de Support the show
